Left ventricular assist device complications: Difference between revisions
Ostermayer (talk | contribs) No edit summary |
Ostermayer (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
==Complications== | ==Complications== | ||
#Driveline infections | #Driveline infections | ||
#Bleeding (many patients are anticoagulated on the LVAD) | |||
#Thrombus formation (due to inappropriate anticoagulation) | |||
#Bleeding | |||
**Acquired Von Willebrand disease (similar to patients on dialysis or with aortic stenosis) | |||
**Hypercoagulability due to coumadin | |||
Revision as of 16:24, 17 July 2013
Background
- Developed in 1960s and used as a bridge to Cardiac Transplant
- Indication is New York Heart Association class 4 heart failure, ejection fraction <25%, VO2 max less than 15 among other criteria.
Mechanism of Action
- External pump unit outside body with intake channel (blood is drained from the apex of the left ventricle) and output channel (blood is ejected into the aorta). Bypasses left ventricle function. BiVAD bypasses both ventricles.
Complications
- Driveline infections
- Bleeding (many patients are anticoagulated on the LVAD)
- Thrombus formation (due to inappropriate anticoagulation)
- Bleeding
- Acquired Von Willebrand disease (similar to patients on dialysis or with aortic stenosis)
- Hypercoagulability due to coumadin